Could a new approach determine the future of cancer treatment?

The latest episode of the DDW 'In Conversation With' series is available to listen to below. This week, Bruno Quinney speaks to Terry Connolly and Shinta Cheng from K36 Therapeutics. K36 is a company developing first-in-class cancer therapeutics and their current lead asset is a treatment for multiple myeloma patients. Bruno speaks to Terry and Shinta about how their NSD2 inhibitors can treat cancer, how their approach compares to other biotechs, and why K36's science could be applied to other therapeutic areas. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.